These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 36420154)
1. Integrative analysis deciphers the heterogeneity of cancer-associated fibroblast and implications on clinical outcomes in ovarian cancers. Zhao Y; Mei S; Huang Y; Chen J; Zhang X; Zhang P Comput Struct Biotechnol J; 2022; 20():6403-6411. PubMed ID: 36420154 [TBL] [Abstract][Full Text] [Related]
2. Identifies microtubule-binding protein Wang W; Zhang J; Wang Y; Xu Y; Zhang S Comput Struct Biotechnol J; 2022; 20():3322-3335. PubMed ID: 35832625 [TBL] [Abstract][Full Text] [Related]
3. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers. Wang N; Zhu L; Wang L; Shen Z; Huang X Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736 [TBL] [Abstract][Full Text] [Related]
4. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas. Zhao S; Li Y; Xu J; Shen L Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705 [TBL] [Abstract][Full Text] [Related]
5. The molecular feature of macrophages in tumor immune microenvironment of glioma patients. Zhang H; Luo YB; Wu W; Zhang L; Wang Z; Dai Z; Feng S; Cao H; Cheng Q; Liu Z Comput Struct Biotechnol J; 2021; 19():4603-4618. PubMed ID: 34471502 [TBL] [Abstract][Full Text] [Related]
6. PreMSIm: An R package for predicting microsatellite instability from the expression profiling of a gene panel in cancer. Li L; Feng Q; Wang X Comput Struct Biotechnol J; 2020; 18():668-675. PubMed ID: 32257050 [TBL] [Abstract][Full Text] [Related]
7. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures. Zhang X; Wang Y; A G; Qu C; Chen J Front Immunol; 2021; 12():721030. PubMed ID: 34531868 [TBL] [Abstract][Full Text] [Related]
8. Violations of proportional hazard assumption in Cox regression model of transcriptomic data in TCGA pan-cancer cohorts. Zeng Z; Gao Y; Li J; Zhang G; Sun S; Wu Q; Gong Y; Xie C Comput Struct Biotechnol J; 2022; 20():496-507. PubMed ID: 35070171 [TBL] [Abstract][Full Text] [Related]
9. A fibroblast-associated signature predicts prognosis and immunotherapy in esophageal squamous cell cancer. Ren Q; Zhang P; Zhang X; Feng Y; Li L; Lin H; Yu Y Front Immunol; 2023; 14():1199040. PubMed ID: 37313409 [TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of tumor necrosis factor-α-inducible protein 8-like 2 (TIPE2): A potential novel pan-cancer immune checkpoint. Bai KH; Zhang YY; Li XP; Tian XP; Pan MM; Wang DW; Dai YJ Comput Struct Biotechnol J; 2022; 20():5226-5234. PubMed ID: 36187930 [TBL] [Abstract][Full Text] [Related]
11. Advancing Pan-cancer Gene Expression Survial Analysis by Inclusion of Non-coding RNA. Ye B; Shi J; Kang H; Oyebamiji O; Hill D; Yu H; Ness S; Ye F; Ping J; He J; Edwards J; Zhao YY; Guo Y RNA Biol; 2020 Nov; 17(11):1666-1673. PubMed ID: 31607216 [TBL] [Abstract][Full Text] [Related]
12. Single-cell and bulk RNA sequencing reveal cancer-associated fibroblast heterogeneity and a prognostic signature in prostate cancer. Liu W; Wang M; Wang M; Liu M Medicine (Baltimore); 2023 Aug; 102(32):e34611. PubMed ID: 37565899 [TBL] [Abstract][Full Text] [Related]
13. The SARS-CoV-2 host cell receptor ACE2 correlates positively with immunotherapy response and is a potential protective factor for cancer progression. Zhang Z; Li L; Li M; Wang X Comput Struct Biotechnol J; 2020; 18():2438-2444. PubMed ID: 32905022 [TBL] [Abstract][Full Text] [Related]
14. Integrative omics analysis reveals relationships of genes with synthetic lethal interactions through a pan-cancer analysis. Guo L; Li S; Qian B; Wang Y; Duan R; Jiang W; Kang Y; Dou Y; Yang G; Shen L; Wang J; Liang T Comput Struct Biotechnol J; 2020; 18():3243-3254. PubMed ID: 33240468 [TBL] [Abstract][Full Text] [Related]
15. Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing. Li T; Zhou Z; Xie Z; Fan X; Zhang Y; Zhang Y; Song X; Ruan Y J Cancer Res Clin Oncol; 2023 Oct; 149(13):11379-11395. PubMed ID: 37369799 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of the novel omicron receptor AXL in cancers. Zhang WN; Li XP; Wang PF; Zhu L; Xiao XH; Dai YJ Comput Struct Biotechnol J; 2022; 20():3304-3312. PubMed ID: 35782741 [TBL] [Abstract][Full Text] [Related]
17. Integrative analyses of bulk and single-cell RNA-seq identified cancer-associated fibroblasts-related signature as a prognostic factor for immunotherapy in NSCLC. Wang S; Fan G; Li L; He Y; Lou N; Xie T; Dai L; Gao R; Yang M; Shi Y; Han X Cancer Immunol Immunother; 2023 Jul; 72(7):2423-2442. PubMed ID: 37010552 [TBL] [Abstract][Full Text] [Related]
18. scRNA-seq characterizing the heterogeneity of fibroblasts in breast cancer reveals a novel subtype SFRP4 Ning L; Quan C; Wang Y; Wu Z; Yuan P; Xie N Front Oncol; 2024; 14():1348299. PubMed ID: 38686196 [TBL] [Abstract][Full Text] [Related]
19. Integrated single-cell and bulk RNA sequencing analyses reveal a prognostic signature of cancer-associated fibroblasts in head and neck squamous cell carcinoma. Yang Y; Ma B; Han L; Xu W; Du X; Wei W; Liao T; Ji Q; Qu N; Wang Y Front Genet; 2022; 13():1028469. PubMed ID: 36568368 [No Abstract] [Full Text] [Related]
20. Immune infiltration and clinical significance analyses of the cancer-associated fibroblast-related signature in skin cutaneous melanoma. Cen X; Li M; Yao A; Zheng Y; Lai W J Gene Med; 2024 Jan; 26(1):e3614. PubMed ID: 37847069 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]